EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pentraxin 3 (Ptx3) As A Novel Biomarker In Type 1 Diabetes With Diabetic Retinopathy

Shereen Abdelghaffar, Ebrahim Mohamed, Ahmed Albalkini, May Selim, Mohamed Ismail

Adolescência e Saúde · 01.08.2026 · 21 (5s) · 845-852

DOI: 10.67440/ahj.v21i5s.1484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Adolescência e Saúde, online erschienen am 01.08.2026. Verfasst von Shereen Abdelghaffar und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetic retinopathy (DR) remains a major microvascular complication of type 1 diabetes mellitus (T1DM), and inflammatory biomarkers such as pentraxin-3 (PTX3) have been proposed as potential indicators of retinal microvascular injury.

Objective

To investigates whether increased plasma PTX3 levels are associated with DR in patients with T1DM and assesses PTX3 as a candidate early biomarker for the detection of DR and for monitoring its progression.

Methods

This case–control analytical study was conducted over 18 months at Cairo University Pediatric Hospital and Kasr Al-Ainy Pediatric University Hospital (Cairo, Egypt). Thirty-six patients with confirmed T1DM were included and allocated into two equal groups based on ophthalmological assessment: DR (n=18) and no DR (n=18). Fundus assessment was performed by a specialized ophthalmologist, and plasma PTX3 was measured using a sandwich ELISA.

Results

Patients with DR were older (23.72±9.9 vs 14.42±3.03 years; p=0.001) and had longer diabetes duration (13.33±6.62 vs 8.22±3.03 years; p=0.017). Mean PTX3 was higher in the DR group (7.27±3.47 vs 5.78±2.81 pg/mL), but the difference was not statistically significant (p=0.282). Diagnostic performance of PTX3 for detecting DR was limited (AUC 0.605; 95% CI 0.414–0.795; p=0.282); at a cutoff of 8.62 pg/mL, sensitivity was 50% and specificity 83%.

Conclusion

In this cohort, plasma PTX3 alone showed limited ability to discriminate DR in T1DM and may be more useful as part of a combined risk-assessment panel rather than a standalone biomarker.

Zitieren

APA

Abdelghaffar, S., Mohamed, E., Albalkini, A., Selim, M., & Ismail, M. (2026). Pentraxin 3 (Ptx3) As A Novel Biomarker In Type 1 Diabetes With Diabetic Retinopathy. Adolescência e Saúde, 21(5s), 845-852. https://doi.org/10.67440/ahj.v21i5s.1484

Vancouver

Abdelghaffar S, Mohamed E, Albalkini A, Selim M, Ismail M. Pentraxin 3 (Ptx3) As A Novel Biomarker In Type 1 Diabetes With Diabetic Retinopathy. Adolescência e Saúde. 2026;21(5s):845-852. doi:10.67440/ahj.v21i5s.1484

BibTeX
@article{Abdelghaffar2026,
  author = {Abdelghaffar, Shereen and Mohamed, Ebrahim and Albalkini, Ahmed and Selim, May and Ismail, Mohamed},
  title = {Pentraxin 3 (Ptx3) As A Novel Biomarker In Type 1 Diabetes With Diabetic Retinopathy},
  journal = {Adolescência e Saúde},
  year = {2026},
  volume = {21},
  number = {5s},
  pages = {845--852},
  doi = {10.67440/ahj.v21i5s.1484}
}
Kostenlos starten →